Rational use of agonists and antagonists of luteinizing hormone-releasing hormone (LH-RH) in the treatment of hormone-sensitive neoplasms and gynaecologic conditions

This publication has 72 references indexed in Scilit:

• Inhibition of luteinizing hormone, follicle-stimulating hormone and sex-steroid levels in men and women with a potent antagonist analog of luteinizing hormone-releasing hormone, Cetrorelix (SB-75)
  Acta Endocrinologica, 1994
• Responses to the antagonistic analog of LH-RH (SB-75, cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer
  The Prostate, 1994
• Cetrorelix < Rec INN >
  Drugs of the Future, 1994
• Clinical Study of Leuprolide Depot Formulation in the Treatment of Advanced Prostate Cancer
  Journal of Urology, 1990
• Endocrine effects of combination antioestrogen and LH-RH agonist therapy in premenopausal patients with advanced breast cancer
  European Journal of Cancer and Clinical Oncology, 1989
• New antagonists of LHRH II. Inhibition and potentiation of LHRH by closely related analogues
  International Journal of Peptide and Protein Research, 1988
• Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects.
  Proceedings of the National Academy of Sciences, 1988
• Comparison of the Potential for Therapeutic Utilities with Gonadotropin-Releasing Hormone Agonists and Antagonists
  Endocrine Reviews, 1986
• Long-acting delivery systems for peptides: inhibition of rat prostate tumors by controlled release of [D-Trp6]luteinizing hormone-releasing hormone from injectable microcapsules.
  Proceedings of the National Academy of Sciences, 1984
• PEPTIDE ANTAGONISTS OF LH-RH: LARGE INCREASES IN ANTIOVULATORY ACTIVITIES PRODUCED BY BASIC D-AMINO ACIDS IN THE SIX POSITION
  Endocrinology, 1982